Chlorphentermine
| Clinical data | |
|---|---|
| Other names | 4-Chlorophentermine; 4-Chloro-α-methylamphetamine; 4-Chloro-α,α-dimethylphenethylamine |
| Routes of administration | Oral |
| Drug class | Serotonin releasing agent; Selective serotonin releasing agent; Appetite suppressant; Anorectic; Anorexic; Anorexiant |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 40 hours–5 days |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.006.651 |
| Chemical and physical data | |
| Formula | C10H14ClN |
| Molar mass | 183.68 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Chlorphentermine, sold under the brand names Apsedon, Desopimon, and Lucofen, is a serotonergic appetite suppressant of the amphetamine family. Developed in 1962, it is the para-chloro derivative of the better-known appetite suppressant phentermine, which is still in current use.
The drug acts as a highly selective serotonin releasing agent (SRA). It is not a psychostimulant and has little or no misuse potential, but is classed as a Schedule III drug in the United States due mainly to its similarity to other appetite suppressants such as diethylpropion which have been more widely misused. It is no longer used due mainly to safety concerns, as it has a serotonergic effects profile similar to other withdrawn appetite suppressants such as fenfluramine and aminorex which were found to cause pulmonary hypertension and cardiac fibrosis following prolonged use.
Chlorphentermine was first synthesized by 1954 and was subsequently developed in the early 1960s. It remained on the market in the United States as late as 2004.